Implementation and Evaluation of a Social Journey Accompanied in Breast Cancer Diagnosis (EPARS SEIN)

Implementation and Evaluation of a Social Journey Accompanied for Women With Breast Cancer Diagnosis

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02893527

Acronym

EPARS-SEIN

Enrollment

Registered

2016-09-08

Start date

2015-02-24

Completion date

2017-12-31

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Evaluate and compare the return to work rate at 12 months

Detailed description

Evaluate and compare the return to work rate at 12 months (from J1C1 \[first day of the first adjuvant chemotherapy regimen\]) between the intervention group (which has accompanied the career) and the standard group course

Interventions

BEHAVIORALpersonalized coaching

personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient major\> 18 * Have a diagnosis of localized breast cancer requiring surgery immediately adjuvant therapy sequence including chemotherapy and radiotherapy * Being more than 3 years of retirement at diagnosis * Have a work contract valid at the time of diagnosis (before surgery) * Do not practice a profession * Be in possession of his rights (excluding guardianship, curatorship) * Raise the general social security scheme and have rights to cash benefits in the Languedoc-Roussillon region

Exclusion criteria

* Patient minor * Patient diagnosed with metastatic breast cancer * Patients refusing to sign the consent * Patients do not have sufficient understanding of the French language * Patients for whom it is impossible to give clear information

Design outcomes

Primary

Measure	Time frame	Description
Evaluate and compare the return to work rate	through study completion, an average of 5 years	Evaluate and compare the return to work rate at 12 months (from J1C1 \[first day of the first adjuvant chemotherapy regimen\]) between the intervention group (which has accompanied the career) and the standard group course

Secondary

Measure	Time frame	Description
describe the conditions of the resumption of work	through study completion, an average of 5 years	The study will also allow to describe the conditions of the resumption of work in 12 months for the patients concerned and to compare these conditions between the 2 groups

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026